Patents by Inventor Martin Béhé

Martin Béhé has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Peptide derivatives of exendin-4
    Patent number: 8268781
    Abstract: In the current invention peptides, which are derived from GLP-1 (glucagon-like peptide-1) and exendin-3 and/or exendin-4, are provided which bond to the GLP-receptor and can be used, labeled or unlabeled, for the production of an agent for diagnostic and therapy of benign and malignant diseases, in which GLP-1 receptor expression plays a role.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: September 18, 2012
    Assignee: Philipps-Universitat Marburg
    Inventors: Martin Gotthardt, Martin Béhé, Thomas Behr, Burkhard J. Göke
  • Invention concerning GLP-1 and exendin
    Publication number: 20090180953
    Abstract: In the current invention peptides, which are derived from GLP-1 (glucagon-like peptide-1) and exendin-3 and/or exendin-4, are provided which bond to the GLP-receptor and can be used, labeled or unlabeled, for the production of an agent for diagnostic and therapy of benign and malignant diseases, in which GLP-1 receptor expression plays a role.
    Type: Application
    Filed: March 2, 2007
    Publication date: July 16, 2009
    Inventors: Martin Gotthardt, Martin Behe, Thomas Behr, Burkhard J. Goke
  • Modified minigastrin analogs for oncology applications
    Publication number: 20070041903
    Abstract: The invention is directed to modified minigastrin analogs. It further relates to labeling such modified minigastrin analogs with metallic radionuclides. The invention further relates to methods for making such novel modified minigastrin analogs, their labeling with metallic radionuclides and their use in oncology applications as in the targeted diagnostic imaging and staging of CCK-2/gastrin-R-positive neoplasms in man with SPECT (technetium-99m), or PET (technetium-94m), or eventually in targeted radionuclide therapy (rhenium-188).
    Type: Application
    Filed: August 19, 2005
    Publication date: February 22, 2007
    Inventors: Theodosia Maina, Berthold Noll, Thomas Behr, Martin BEHE